Helen Ruth Stagg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Helen Ruth Stagg has a total of 471 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Abubakar
Faculty of Population Health Sciences, University College London, London, UK
22 shared publications - Marc Lipman
UCL Respiratory, Division of Medicine, University College London, London, UK
19 shared publications Ibrahim Abubakar
Institute for Global Health, University College London, London, UK
9 shared publications- Joanne R. Winter
Institute for Global Health, University College London, London, UK
8 shared publications - Charlotte Jackson
Innovative Clinical Trials Unit at UCL, University College London, London, UK
6 shared publications - Dominik Zenner
Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
5 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by BMJ in BMJ Global Health
- Vol. 11 (6) , e020365
Multimorbidity and the risk of post-tuberculosis lung disease: a systematic review and meta-analysis
Introduction: Post-tuberculosis lung disease (PTLD), a chronic respiratory syndrome affecting approximately half of tuberculosis (TB) survivors, is an emerging public health threat in low- and middle-income countries (LMICs). Multimorbidity, defined as two or more coexisting chronic health conditions, is also rising in LMICs. This systematic review and meta-analysis examines associations between multimorbidity or individual comorbidities and PTLD. Methods: Medline, EMBASE, Web of Science, Global Health and Scopus databases up to 7 March 2024 were searched and studies in LMICs assessing PTLD and either a single comorbidity or multimorbidity were included. Summary data were extracted independently by two reviewers. Random effects meta-analyses were performed where sufficient comparable data were reported. Risk of bias was assessed using Risk Of Bias in Non-randomised Studies-of Exposure and certainty of evidence for meta-analysable associations was assessed using Grading of Recommendations Assessment, Development and Evaluation. Study protocol was registered with PROSPERO (CRD42024552486). Results: 41 papers, from 10 321 screened, were included. None analysed multimorbidity. PTLD measurement tools varied widely. Meta-analysis of 10 of 24 papers analysing the association between spirometry-defined PTLD and HIV status found reduced odds of PTLD in people living with HIV (OR 0.68, 95% CI 0.52 to 0.89). 15 papers reported on diabetes and showed inconsistent associations; meta-analysis of three papers yielded an OR of 1.65 (95% CI 0.96 to 2.84). Adults with undernutrition had increased odds of abnormal spirometry following TB on meta-analysis of three studies (OR 1.99, 95% CI 1.02 to 3.87). Evidence for other comorbidities was limited and inconclusive. Overall, 24/41 (58.5%) of included studies were at high risk of bias and certainty of evidence for meta-analysed associations was very low. Conclusion: PTLD may be more common among adults who are HIV-negative or undernourished, but the evidence is very uncertain. The absence of dedicated multimorbidity studies and inconsistencies in defining PTLD highlight the need for prospective studies evaluating comorbidities in relation to PTLD. PROSPERO registration number: CRD42024552486.
- 1 June 2026
- Published by BMJ in BMJ Global Health
- Vol. 11 (6) , e020365
Open AccessMultimorbidity and the risk of post-tuberculosis lung disease: a systematic review and meta-analysis
Introduction: Post-tuberculosis lung disease (PTLD), a chronic respiratory syndrome affecting approximately half of tuberculosis (TB) survivors, is an emerging public health threat in low- and middle-income countries (LMICs). Multimorbidity, defined as two or more coexisting chronic health conditions, is also rising in LMICs. This systematic review and meta-analysis examines associations between multimorbidity or individual comorbidities and PTLD. Methods: Medline, EMBASE, Web of Science, Global Health and Scopus databases up to 7 March 2024 were searched and studies in LMICs assessing PTLD and either a single comorbidity or multimorbidity were included. Summary data were extracted independently by two reviewers. Random effects meta-analyses were performed where sufficient comparable data were reported. Risk of bias was assessed using Risk Of Bias in Non-randomised Studies-of Exposure and certainty of evidence for meta-analysable associations was assessed using Grading of Recommendations Assessment, Development and Evaluation. Study protocol was registered with PROSPERO (CRD42024552486). Results: 41 papers, from 10 321 screened, were included. None analysed multimorbidity. PTLD measurement tools varied widely. Meta-analysis of 10 of 24 papers analysing the association between spirometry-defined PTLD and HIV status found reduced odds of PTLD in people living with HIV (OR 0.68, 95% CI 0.52 to 0.89). 15 papers reported on diabetes and showed inconsistent associations; meta-analysis of three papers yielded an OR of 1.65 (95% CI 0.96 to 2.84). Adults with undernutrition had increased odds of abnormal spirometry following TB on meta-analysis of three studies (OR 1.99, 95% CI 1.02 to 3.87). Evidence for other comorbidities was limited and inconclusive. Overall, 24/41 (58.5%) of included studies were at high risk of bias and certainty of evidence for meta-analysed associations was very low. Conclusion: PTLD may be more common among adults who are HIV-negative or undernourished, but the evidence is very uncertain. The absence of dedicated multimorbidity studies and inconsistencies in defining PTLD highlight the need for prospective studies evaluating comorbidities in relation to PTLD. PROSPERO registration number: CRD42024552486.
- Top Cited PapersOpen Access
- 25 April 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (3) , e70153
Beyond the Usual Suspects: Emerging Associations Between Epstein‐Barr Virus Infection/Infectious Mononucleosis and Cancers
Epstein‐Barr virus (EBV) is a ubiquitous herpesvirus and a causal factor for Burkitt Lymphoma (BL), Hodgkin Lymphoma (HL), gastric carcinoma (GC) and nasopharyngeal carcinoma (NPC). Whether EBV contributes to a wider spectrum of cancers remains uncertain. We reviewed MEDLINE, Embase and Web of Science on 30 th July 2024 to identify observational studies that examined the association between EBV infection or EBV‐infectious mononucleosis (IM) and cancers beyond BL, HL, GC and NPC. Evidence was appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. For cancers meeting minimum thresholds we assessed etiologic fractions (EFs), biological plausibility, epidemiological burden, latency after IM, and predictive biomarkers. Thirty‐three eligible studies were identified, yielding 13 hypotheses (i.e., specific potential reported associations between EBV infection or IM and individual cancer types) that advanced through GRADE. Breast cancer and NHL had the greatest weight of biological plausibility, cervical and prostate the least. Despite an array of tests, testicular cancer studies provided limited evidence. EFs ranged between 12.3% (IM‐breast) and 85.1% (EBV infection‐NHL). Breast and prostate cancers had the highest global incidence. Only one study (for NHL) provided data on time from IM to cancer onset, and prostate‐specific antigen was the only biomarker identified. In this review, we highlight eight cancers across six cancer groups (breast, cervical, leukaemia/other haematologic, NHL, prostate, testicular) with some evidence of EBV involvement. These results reinforce the potential long‐term value of EBV vaccine development, while emphasising the need for high‐quality prospective studies with robust methods of viral detection to establish causality.
- 25 April 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (3) , e70153
Top Cited PapersOpen AccessBeyond the Usual Suspects: Emerging Associations Between Epstein‐Barr Virus Infection/Infectious Mononucleosis and Cancers
Epstein‐Barr virus (EBV) is a ubiquitous herpesvirus and a causal factor for Burkitt Lymphoma (BL), Hodgkin Lymphoma (HL), gastric carcinoma (GC) and nasopharyngeal carcinoma (NPC). Whether EBV contributes to a wider spectrum of cancers remains uncertain. We reviewed MEDLINE, Embase and Web of Science on 30 th July 2024 to identify observational studies that examined the association between EBV infection or EBV‐infectious mononucleosis (IM) and cancers beyond BL, HL, GC and NPC. Evidence was appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. For cancers meeting minimum thresholds we assessed etiologic fractions (EFs), biological plausibility, epidemiological burden, latency after IM, and predictive biomarkers. Thirty‐three eligible studies were identified, yielding 13 hypotheses (i.e., specific potential reported associations between EBV infection or IM and individual cancer types) that advanced through GRADE. Breast cancer and NHL had the greatest weight of biological plausibility, cervical and prostate the least. Despite an array of tests, testicular cancer studies provided limited evidence. EFs ranged between 12.3% (IM‐breast) and 85.1% (EBV infection‐NHL). Breast and prostate cancers had the highest global incidence. Only one study (for NHL) provided data on time from IM to cancer onset, and prostate‐specific antigen was the only biomarker identified. In this review, we highlight eight cancers across six cancer groups (breast, cervical, leukaemia/other haematologic, NHL, prostate, testicular) with some evidence of EBV involvement. These results reinforce the potential long‐term value of EBV vaccine development, while emphasising the need for high‐quality prospective studies with robust methods of viral detection to establish causality.
- Open Access
- 20 February 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 04085
Development of a clinical algorithm-based scoring system to diagnose smear-negative pulmonary tuberculosis in Sabah, Malaysia using the modified Delphi method
Tuberculosis (TB) remains a major global public health problem, accounting for an estimated 10.8 million infections and 1.25 million people deaths worldwide in 2023, with over 80% occurring in low- and middle-income countries [1]. There was an upward trend in TB incidence globally following the COVID-19 pandemic, with most new cases occurring in the […]
- 20 February 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 04085
Open AccessDevelopment of a clinical algorithm-based scoring system to diagnose smear-negative pulmonary tuberculosis in Sabah, Malaysia using the modified Delphi method
Tuberculosis (TB) remains a major global public health problem, accounting for an estimated 10.8 million infections and 1.25 million people deaths worldwide in 2023, with over 80% occurring in low- and middle-income countries [1]. There was an upward trend in TB incidence globally following the COVID-19 pandemic, with most new cases occurring in the […]
- Open Access
- 2 February 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (6) , 1615-1623
Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence
Hepatitis C virus (HCV) infection is associated with unfavorable multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) outcomes. We examined whether this association would decrease in settings where no participants were lost-to-follow-up or where all adhered to regimens comprised of priority TB drugs. We analyzed data from 1,530 participants with HCV testing in the endTB observational cohort (NCT03259269). We estimated the relative risk of death, treatment failure, and loss-to-follow-up comparing participants with and without HCV, using inverse probability weighting to adjust for confounding. We then estimated relative risks of HCV on death and failure in weighted pseudopopulations representing hypothetical interventions eliminating loss-to-follow-up and ensuring adherence to strong MDR/RR-TB regimens. The unadjusted risk difference comparing participants with and without HCV was 14.1% (95% confidence interval [CI], 8.0%-20.1%), decreasing to 11.0% (95% CI, 3.0%-19.1%) after weighting. In pseudopopulations without loss-to-follow-up or with adequate adherence to strong regimens, the risk differences were 7.7% (95% CI, 0.8%-16.2%) and 7.0% (95% CI,−1.6% to 17.3%), respectively. Adjustment for baseline confounders attenuated the association between HCV and unfavorable outcomes, suggesting these factors partly explain the disparity. Further attenuation after eliminating loss-to-follow-up suggests that improving treatment retention in MDR/RR-TB care may reduce outcome disparities among patients with HCV.
- 2 February 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (6) , 1615-1623
Open AccessEstimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence
Hepatitis C virus (HCV) infection is associated with unfavorable multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) outcomes. We examined whether this association would decrease in settings where no participants were lost-to-follow-up or where all adhered to regimens comprised of priority TB drugs. We analyzed data from 1,530 participants with HCV testing in the endTB observational cohort (NCT03259269). We estimated the relative risk of death, treatment failure, and loss-to-follow-up comparing participants with and without HCV, using inverse probability weighting to adjust for confounding. We then estimated relative risks of HCV on death and failure in weighted pseudopopulations representing hypothetical interventions eliminating loss-to-follow-up and ensuring adherence to strong MDR/RR-TB regimens. The unadjusted risk difference comparing participants with and without HCV was 14.1% (95% confidence interval [CI], 8.0%-20.1%), decreasing to 11.0% (95% CI, 3.0%-19.1%) after weighting. In pseudopopulations without loss-to-follow-up or with adequate adherence to strong regimens, the risk differences were 7.7% (95% CI, 0.8%-16.2%) and 7.0% (95% CI,−1.6% to 17.3%), respectively. Adjustment for baseline confounders attenuated the association between HCV and unfavorable outcomes, suggesting these factors partly explain the disparity. Further attenuation after eliminating loss-to-follow-up suggests that improving treatment retention in MDR/RR-TB care may reduce outcome disparities among patients with HCV.
- Open Access
- 25 December 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003777
Effect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: a multicountry cohort study
Background: People who smoke are at increased risk of unfavourable tuberculosis treatment outcomes compared with those who do not, but the pathways that explain this disparity are unclear. Objective: To estimate the difference in a successful end-of-treatment outcome by smoking status among people with multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) and to examine if this difference changes if people who smoked had the same retention in treatment as those who did not smoke. Design and methods: Using data from the prospective endTB Observational Study, we estimated the difference in treatment success by cigarette smoking status, adjusting for baseline confounders including demographics, social history and comorbidities. To examine how this difference changed if everyone was retained in treatment, we censored participants who were lost to follow-up and applied inverse probability of censoring weights to simulate this scenario. Results: Among 1786 participants in 12 countries, 539 (30.2%) reported smoking at least one cigarette daily. People who smoked were more frequently found in post-Soviet countries and had a complex social history (eg, incarceration and substance use) and infectious comorbidities (eg, hepatitis C). At the end of treatment, 73.5% of people who smoked and 80.3% of people who did not smoke had treatment success (risk difference in percentage points: −6.8, 95% CI −11.1 to –2.6). After adjusting for baseline confounders, the risk difference was similar (−5.2 percentage points), but the 95% CI was less precise (−14.1 to 3.2). When simulating a scenario in which everyone was retained in treatment, the risk difference was attenuated (−1.9 percentage points; 95% CI −11.1 to 4.7). Conclusion: People who smoked had a lower frequency of MDR/RR-TB treatment success than those who did not smoke. Eliminating loss to follow-up reduced this difference by smoking status, suggesting that pathways related to retention in treatment were a major driver of this disparity.
- 25 December 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003777
Open AccessEffect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: a multicountry cohort study
Background: People who smoke are at increased risk of unfavourable tuberculosis treatment outcomes compared with those who do not, but the pathways that explain this disparity are unclear. Objective: To estimate the difference in a successful end-of-treatment outcome by smoking status among people with multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) and to examine if this difference changes if people who smoked had the same retention in treatment as those who did not smoke. Design and methods: Using data from the prospective endTB Observational Study, we estimated the difference in treatment success by cigarette smoking status, adjusting for baseline confounders including demographics, social history and comorbidities. To examine how this difference changed if everyone was retained in treatment, we censored participants who were lost to follow-up and applied inverse probability of censoring weights to simulate this scenario. Results: Among 1786 participants in 12 countries, 539 (30.2%) reported smoking at least one cigarette daily. People who smoked were more frequently found in post-Soviet countries and had a complex social history (eg, incarceration and substance use) and infectious comorbidities (eg, hepatitis C). At the end of treatment, 73.5% of people who smoked and 80.3% of people who did not smoke had treatment success (risk difference in percentage points: −6.8, 95% CI −11.1 to –2.6). After adjusting for baseline confounders, the risk difference was similar (−5.2 percentage points), but the 95% CI was less precise (−14.1 to 3.2). When simulating a scenario in which everyone was retained in treatment, the risk difference was attenuated (−1.9 percentage points; 95% CI −11.1 to 4.7). Conclusion: People who smoked had a lower frequency of MDR/RR-TB treatment success than those who did not smoke. Eliminating loss to follow-up reduced this difference by smoking status, suggesting that pathways related to retention in treatment were a major driver of this disparity.
- Open Access
- 14 August 2025
- Vol. 10 (8)
Equity in protection: bridging global data gaps for an EBV vaccine-a systematic review and meta-analysis.
Epstein-Barr virus (EBV) is linked to multiple malignancies and autoimmune conditions, with different disease burdens globally. Pharmaceutical companies and researchers are placing substantial investment in the development of EBV vaccines. To ensure optimal vaccine roll-out, particularly in resource-limited settings, it is essential to have data on the age at acquisition of EBV. This study aimed to systematically review and meta-analyse seroprevalence by age and country, WHO region and country income level, identify knowledge gaps, and determine an approach to bridge these gaps. MEDLINE, Embase and Web of Science were searched on 22 March 2022 for studies that measured EBV seroprevalence by age. An updated search was conducted on 22 October 2022. There were no language restrictions. Papers were assessed for quality using an adapted version of the Downs and Black checklist. Seroprevalence by age was estimated using a fixed-effect (country) or random-effects (WHO region and income) meta-analysis. This review has been registered on PROSPERO (CRD42022349900). Only one country (USA) had enough data for a country meta-analysis. WHO regional analyses revealed the Western Pacific region to have a higher seroprevalence in younger age groups than other WHO regions. Country income level better explained seroprevalence trends per age. Middle-income countries displayed a quicker rise to balance seroprevalence than high-income countries, with a 30% absolute increase in 0- to 4-year-olds in middle-income than in high-income countries (59% [95% CI 28 to 91%, I2=99%] vs 29% [95% CI 16 to 41%, I2=99%]). This first meta-analysis producing estimates of EBV seroprevalence by age provides crucial information to guide governments when using a vaccine for EBV. However, data variability and limited consistency of methodologies and EBV seroprevalence measurements hindered comprehensive meta-analyses across all WHO regions and countries. This study provides an interim framework for the extrapolation of seroprevalence using country-specific income levels to aid vaccine roll-out decisions. CRD42022349900.
- 14 August 2025
- Vol. 10 (8)
Open AccessEquity in protection: bridging global data gaps for an EBV vaccine-a systematic review and meta-analysis.
Epstein-Barr virus (EBV) is linked to multiple malignancies and autoimmune conditions, with different disease burdens globally. Pharmaceutical companies and researchers are placing substantial investment in the development of EBV vaccines. To ensure optimal vaccine roll-out, particularly in resource-limited settings, it is essential to have data on the age at acquisition of EBV. This study aimed to systematically review and meta-analyse seroprevalence by age and country, WHO region and country income level, identify knowledge gaps, and determine an approach to bridge these gaps. MEDLINE, Embase and Web of Science were searched on 22 March 2022 for studies that measured EBV seroprevalence by age. An updated search was conducted on 22 October 2022. There were no language restrictions. Papers were assessed for quality using an adapted version of the Downs and Black checklist. Seroprevalence by age was estimated using a fixed-effect (country) or random-effects (WHO region and income) meta-analysis. This review has been registered on PROSPERO (CRD42022349900). Only one country (USA) had enough data for a country meta-analysis. WHO regional analyses revealed the Western Pacific region to have a higher seroprevalence in younger age groups than other WHO regions. Country income level better explained seroprevalence trends per age. Middle-income countries displayed a quicker rise to balance seroprevalence than high-income countries, with a 30% absolute increase in 0- to 4-year-olds in middle-income than in high-income countries (59% [95% CI 28 to 91%, I2=99%] vs 29% [95% CI 16 to 41%, I2=99%]). This first meta-analysis producing estimates of EBV seroprevalence by age provides crucial information to guide governments when using a vaccine for EBV. However, data variability and limited consistency of methodologies and EBV seroprevalence measurements hindered comprehensive meta-analyses across all WHO regions and countries. This study provides an interim framework for the extrapolation of seroprevalence using country-specific income levels to aid vaccine roll-out decisions. CRD42022349900.
- Open Access
- 11 August 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3461-3470
Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study
Aims: Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses. Methods: In this retrospective cohort study, adults (≥18 years) who began the standard 6‐month drug‐sensitive anti‐TB regimen in an outpatient facility in Riga, Latvia (May 2015–September 2022) and missed at least one dose of treatment were included. Data were collected from medical records and observed therapy records. Missed doses were subdivided into early discontinuation or sporadically missed. Descriptive analyses and lasagne plots were used. Results: Across 174 patients, 54 (31.0%, CI: 24.2–37.9%) missed doses due to ADRs. Of 31 320 doses, 4217 (13.5%, CI: 13.1–13.9%) were missed, 20.9% (880/4217, CI: 19.6–22.1%) were due to ADRs. Eighteen (10.3%) of the 174 patients discontinued treatment early, two of which (11.1%) were due to ADRs. Doses missed due to ADRs caused longer yet less frequent periods of sporadic missed doses: 56.4% (479/849) of sporadic missed doses were 1 day in length vs . only 9.1% (7/77) for ADR‐related ones. Hepatobiliary disorders were the leading ADR group causing missed doses. Hepatobiliary ADRs caused long median durations of missed doses (median 15.0, CI: 13.0–22.0). Conclusion: Our study underscores the importance of ADRs as a cause of missed doses of treatment, particularly hepatobiliary disorders. Regimens that are less prone to ADRs and strong healthcare system support structures for patients with ADRs are required to minimize missed doses, reducing unfavourable outcomes.
- 11 August 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3461-3470
Open AccessAdverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study
Aims: Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses. Methods: In this retrospective cohort study, adults (≥18 years) who began the standard 6‐month drug‐sensitive anti‐TB regimen in an outpatient facility in Riga, Latvia (May 2015–September 2022) and missed at least one dose of treatment were included. Data were collected from medical records and observed therapy records. Missed doses were subdivided into early discontinuation or sporadically missed. Descriptive analyses and lasagne plots were used. Results: Across 174 patients, 54 (31.0%, CI: 24.2–37.9%) missed doses due to ADRs. Of 31 320 doses, 4217 (13.5%, CI: 13.1–13.9%) were missed, 20.9% (880/4217, CI: 19.6–22.1%) were due to ADRs. Eighteen (10.3%) of the 174 patients discontinued treatment early, two of which (11.1%) were due to ADRs. Doses missed due to ADRs caused longer yet less frequent periods of sporadic missed doses: 56.4% (479/849) of sporadic missed doses were 1 day in length vs . only 9.1% (7/77) for ADR‐related ones. Hepatobiliary disorders were the leading ADR group causing missed doses. Hepatobiliary ADRs caused long median durations of missed doses (median 15.0, CI: 13.0–22.0). Conclusion: Our study underscores the importance of ADRs as a cause of missed doses of treatment, particularly hepatobiliary disorders. Regimens that are less prone to ADRs and strong healthcare system support structures for patients with ADRs are required to minimize missed doses, reducing unfavourable outcomes.
- Open Access
- 31 July 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003088
Temporal complexity in missed doses of rifampicin-sensitive anti-tuberculosis treatment: a prospective cohort study in Tanzania
Background: Non-adherence to anti-tuberculosis (TB) regimens is not simplistic; rather, doses are missed in complex patterns. In a cohort of individuals being treated for rifampicin-sensitive pulmonary TB in Tanzania, we sought to examine how doses were missed across the treatment course and within a day, as well as the reasons for missed dose periods. Methods: 200 participants aged ≥18 years treated with the standard 6-month regimen were recruited from March 2022 to June 2023. Missed doses were measured using evriMED pillboxes and by pill count. The reasons for up to three missed dose periods per month were collected. Patterns of missed doses—across treatment and within a day—and their reasons were visualised and described. Findings: Two participants died early in treatment, leaving 198 with missed dose data. The increase in the percentage of participants that missed any given dose as time progressed was driven by early discontinuation (median doses missed 0.0% in month 1 vs 6.7% in month 6) from treatment, as opposed to sporadic missed doses (median doses missed 3.1% in month 1 vs 4.1% in month 6). There was a median of one sporadic missed dose period (ranging between 0 and 42 doses in length) per participant. Out of all the reported reasons for missed dose periods, forgetting or forgetting and inconvenience were the most common (59.6%). Interpretation: Missing doses of anti-TB treatment is a temporally complex phenomenon and the result of the intersection of multifaceted day-to-day events in an individual’s life, with complicated implications for effective drug levels across the treatment course. This complexity limits our ability to predict an individual’s missed doses at the start of treatment.
- 31 July 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003088
Open AccessTemporal complexity in missed doses of rifampicin-sensitive anti-tuberculosis treatment: a prospective cohort study in Tanzania
Background: Non-adherence to anti-tuberculosis (TB) regimens is not simplistic; rather, doses are missed in complex patterns. In a cohort of individuals being treated for rifampicin-sensitive pulmonary TB in Tanzania, we sought to examine how doses were missed across the treatment course and within a day, as well as the reasons for missed dose periods. Methods: 200 participants aged ≥18 years treated with the standard 6-month regimen were recruited from March 2022 to June 2023. Missed doses were measured using evriMED pillboxes and by pill count. The reasons for up to three missed dose periods per month were collected. Patterns of missed doses—across treatment and within a day—and their reasons were visualised and described. Findings: Two participants died early in treatment, leaving 198 with missed dose data. The increase in the percentage of participants that missed any given dose as time progressed was driven by early discontinuation (median doses missed 0.0% in month 1 vs 6.7% in month 6) from treatment, as opposed to sporadic missed doses (median doses missed 3.1% in month 1 vs 4.1% in month 6). There was a median of one sporadic missed dose period (ranging between 0 and 42 doses in length) per participant. Out of all the reported reasons for missed dose periods, forgetting or forgetting and inconvenience were the most common (59.6%). Interpretation: Missing doses of anti-TB treatment is a temporally complex phenomenon and the result of the intersection of multifaceted day-to-day events in an individual’s life, with complicated implications for effective drug levels across the treatment course. This complexity limits our ability to predict an individual’s missed doses at the start of treatment.
- 3 July 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (1) , 2500902
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment
- 3 July 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (1) , 2500902
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment
- Open Access
- 15 February 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e001894
Quantifying non-adherence to anti-tuberculosis treatment due to early discontinuation: a systematic literature review of timings to loss to follow-up
Background The burden of non-adherence to anti-tuberculosis (TB) treatment is poorly understood. One type is early discontinuation, that is, stopping treatment early. Given the implications of early discontinuation for treatment outcomes, we undertook a systematic review to estimate its burden, using the timing of loss to follow-up (LFU) as a proxy measure. Methods Web of Science, Embase and Medline were searched up to 14 January 2021 using terms covering LFU, TB and treatment. Studies of adults (≥ 18 years) on the standard regimen for drug-sensitive TB reporting the timing of LFU (WHO definition) were included. A narrative synthesis was conducted and quality assessment undertaken using an adapted version of Downs and Black. Papers were grouped by the percentage of those who were ultimately LFU who were LFU by 2 months. Three groups were created: Results We found 40 relevant studies from 21 countries. The timing of LFU was variable within and between countries. 36/40 papers (90.0%) reported the percentage of patients LFU by the end of 2 months. 31/36 studies (86.1%) reported a higher than or as expected percentage of patients becoming LFU by 2 months. The percentage of dose-months missed by patients who became LFU ranged between 37% and 77% (equivalent to 2.2–4.6 months). Among all patients, the percentage of dose-months missed ranged between 1% and 22% (equivalent to 0.1–1.3 months). Conclusions A larger than expected percentage of patients became LFU within the first 2 months of treatment. These patients missed high percentages of dose months of treatment due to early discontinuation. Interventions to promote adherence and retain patients in care must not neglect the early months of treatment. PROSPERO registration number CRD42021218636.
- 15 February 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e001894
Open AccessQuantifying non-adherence to anti-tuberculosis treatment due to early discontinuation: a systematic literature review of timings to loss to follow-up
Background The burden of non-adherence to anti-tuberculosis (TB) treatment is poorly understood. One type is early discontinuation, that is, stopping treatment early. Given the implications of early discontinuation for treatment outcomes, we undertook a systematic review to estimate its burden, using the timing of loss to follow-up (LFU) as a proxy measure. Methods Web of Science, Embase and Medline were searched up to 14 January 2021 using terms covering LFU, TB and treatment. Studies of adults (≥ 18 years) on the standard regimen for drug-sensitive TB reporting the timing of LFU (WHO definition) were included. A narrative synthesis was conducted and quality assessment undertaken using an adapted version of Downs and Black. Papers were grouped by the percentage of those who were ultimately LFU who were LFU by 2 months. Three groups were created: Results We found 40 relevant studies from 21 countries. The timing of LFU was variable within and between countries. 36/40 papers (90.0%) reported the percentage of patients LFU by the end of 2 months. 31/36 studies (86.1%) reported a higher than or as expected percentage of patients becoming LFU by 2 months. The percentage of dose-months missed by patients who became LFU ranged between 37% and 77% (equivalent to 2.2–4.6 months). Among all patients, the percentage of dose-months missed ranged between 1% and 22% (equivalent to 0.1–1.3 months). Conclusions A larger than expected percentage of patients became LFU within the first 2 months of treatment. These patients missed high percentages of dose months of treatment due to early discontinuation. Interventions to promote adherence and retain patients in care must not neglect the early months of treatment. PROSPERO registration number CRD42021218636.